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ABSTRACT
Acute inflammation is a natural biological defensive response against infection,
irritation, and injury. While inflammation is a natural process, chronic tissue
inflammation has been implicated in the development of several different diseases. With
the intent of minimizing collateral damage associated with long-term exposure of healthy
tissues to anti-inflammatory drugs, the Pedigo laboratory has designed a system for the
self-assembly of protein polymers as scaffolds for controlled-release of drugs to affected
tissues. This protein polymer comprises two essential components, with the first
component being the calcium-dependent protein, calmodulin, and the second being a
corresponding binding peptide, M13. Because Calmodulin has a specific, high affinity
for the M13 peptide, and because the human body has an inherently high concentration of
extracellular calcium, we expect that the two polymers will interact in a calciumdependent manner forming a supramolecular polymeric matrix. This protein-based
matrix will be covalently modified with anti-inflamatory agents like asprin or ibuprofen.
Assembling this system at the site of chronic inflammation will allow for the controlled
in situ delivery of medication, which would in turn significantly reduce dosage and
eliminate the adverse effects accompanying systemic delivery of medications. An
essential component of this nascent research is determining the toxicity of the protein
scaffold. Through collaboration with Dr. Shabana Khan in the Natural Products Center,
made possible by funding from the Sally McDonnell Barksdale Honors College, access to
state of the art cell toxicity assays and several different cell lines has been made available
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for testing. The objective of this thesis is to perform cytotoxicity tests to demonstrate the
viability of human cell lines when co-cultured with the self-assembling peptides, peptide
derivatives, and peptide-polymer conjugates that compose the self-assembling
biomaterial. This research is the first step for the foundation of further investigation into
the in vivo safety of the biomaterials under development.
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CHAPTER 1
OBJECTIVES
The goal of our laboratory is to create a protein-scaffold based biomaterial for in situ
drug delivery. This material requires that two protomers of our design interact in vivo to
create a the scaffold. These protomers will be covalently modified with drugs. Once
assembled into a matrix, they will serve as a drug depot that will slowly release drug at
the sight of inflammation, for example. The purpose of the work reported in this
document is to establish early in the development of the protein-based scaffold whether
the scaffold itself is toxic to mammalian cells. The development of this assay is
investigated in the following four objectives.
Objective 1
The first step is the verification of correctly constructed protein and peptide
biomaterials. Protein and peptide polymers seen in Figure 1 are to be constructed in the
Pedigo laboratory following the respective protocol for each.

Figure 1: Schematic of design for the M13 and CaM biomaterials
The M13 and CaM biomaterials are designed in such a way that when taken up in
an increased Ca2+ solution, interactions between the protein and peptides will cause the
formation of a matrix-like scaffold. The CaM and M13 interaction is the junction point
between the polymers that are formed, as seen in Figure 2.
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Figure 2: Calcium induces matrix formation
Objective 2
Once the biomaterials have been constructed, multiple cell lines must be cultured for
testing. This requires collaboration with Dr. Shabana Khan and her team of scientists that
have several different cell lines used for testing various materials. While there are
various different cell lines available for testing, choosing the correct one for testing of our
biomaterials is crucial. Two different critical tissues in the body that are particularly
vulnerable are the kidney and the liver. Due to their normal physiological functions in
filtration and processing of diverse materials, they are exposed to exogenous chemicals
and must be metabolically active. Therefore, since they are the most vulnerable, they are
also the most important to study in this toxicity assay. Through discussion with Dr. Khan
and her team, liver and kidney cell lines have been chosen for testing.
Objective 3
In order to test the biomaterials, they must be co-cultured with cells for a period of
time and then tested for toxicity with an MTT assay. The MTT assay materials and
protocol have been made available through collaboration with Claire Tran-Tran, a
researcher in the Khan Laboratories. This assay will test for cell activity after introduced
to the biomaterials for differing time periods.
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Objective 4
The final step is to interpret the results from the assays and to determine levels of
toxicity and viability of the human cells after exposure to the biomaterials. CaM and
M13 are normally intracellular proteins. However, our constructed protein and peptide
will not affect normal intracellular function of CaM and its physiological targets that it
normally regulates. Instead, our materials assemble and function in the extracellular
space; therefore, it is important to study the effects of these biomaterials on the cells from
an extracellular standpoint.
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CHAPTER 2
INTRODUCTION TO BIOMATERIALS
Calmodulin
Calmodulin is an essential component of one of the two unique protein polymers that
will be developed and used in the assembly of the biomaterial scaffold. The fundamental
aim of this research project as a whole is to exploit several ideal characteristics of
Calmodulin that will allow for the self-assembly of a supramolecular polymeric network
for the intended use of in situ drug delivery.
Firstly, one of the main benefits to calmodulin is that it is a 148 residue, acidic
intracellular protein that is one of the most well studied proteins of the last 30 years [1].
Another distinct advantage of calmodulin lies in its extreme sensitivity to calcium
concentrations. The Kd for calcium binding to calmodulin is ~1 µM in the C-terminal
sites and ~10 µM in the N-terminal sites [2]. This evidently shows that both ends of the
calmodulin protein bind calcium with a relatively high affinity, as seen in Figure 3.

Figure 3: Ribbon diagram of CaM saturated with Ca2+ at all four binding sites [3, 4].
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To prove the point of calcium sensitivity even further, calmodulin also functions as
the calcium-sensitive regulatory unit for a number of signal transduction pathways [1]. It
is the high affinity, calcium dependent association with these binding partners that makes
calmodulin so crucial to this study is the biological functions of recognition and
regulation of other protein molecules [5].
Calmodulin is an intracellular Ca2+ receptor protein which regulates a variety of
cellular enzymes and processes including cyclic nucleotide phosphodiesterase, adenylate
cyclase, phospholipase A2, Ca2+-ATPase, phosphorylase kinase, neurotransmitter release,
phosphorylation of membranes, the disassembly of microtubules, and Ca2+ transport [6].
Because alterations in cellular Ca2+ fluxes have been implicated to be involved in steps
leading to irreversible cell damage [6], and because calmodulin participates in the
regulation of the flux of calcium within cells, the relationship between toxicity and
alterations of calcium and calmodulin levels must be explored [6]. While inhibition of
calcium uptake and inhibition of calmodulin function can prove deadly within cells, the
calmodulin biomaterials in this research project are not intended for intracellular use.
The biomaterial will be injected under the skin and be surrounded by cells, but the
biomaterial matrix itself will be outside of the cells. Even though CaM is a natural and
essential intracellular protein, it may induce a response when found within the
extracellular space. That is what this assay is intended to study, is the effect of the
biomaterials on the cells in an extracellular environment.
Binding Peptide
There are several different calmodulin-binding peptides that demonstrate differing
degrees of binding affinities to calmodulin. One of the most well studied binding
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partners is the peptide from skeletal muscle myosin light chain kinase called M13 [7]. It
has also been demonstrated that CaM has the ability to bind peptide substrates, such as
M13, via hydrophobic pockets within each domain [8]. This partner was chosen due to
the depth of literature that has dissected the importance of specific non-covalent forces in
stabilizing the M13-CaM interaction. What is so interesting about the peptide-binding
partner is that we have the ability to change the sequence in order to control the binding
affinity for CaM [9]; and the binding affinities for peptides to saturated calmodulin vary
from 0.3 nM [5] to 70nM [10]. Given that the M13-CaM interactions are primarily
hydrophobic interactions [8], their association constant is independent of pH [11], but
dependent upon the placement of hydrophobic residues [12]. Thus, based on a long
history of investigation we have the ability to specifically tune the interactions between
CaM and M13 to optimize scaffold assembly and stability.
Early structural studies involving NMR and X-ray crystallography have also
demonstrated that M13, which is normally disordered, becomes helical, and CaM
becomes more compact upon binding [13]. When introduced in solution along with
calcium, the protein and peptide will come together to form a collagen-like matrix that
will be the biomaterial used for the in situ drug delivery. Our current studies will consider
only the use of the wild-type peptide. This wild-type peptide consists of 26 residues, as
seen in Figure 4.

KRRWKKNFIAVSAANRFKKISSSGAL
Figure 4. The amino acid sequence of M13 peptide
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Protein and Peptide Matrix
We seek to develop two protein-based alternating polymers that incorporate either
CaM or M13 peptide as structural units, thereby exploiting the natural calcium-dependent
binding of CaM and the peptide M13 as a mechanism for self-assembly of the proposed
biomaterial, as seen in Figure 2. The protein and peptide will come together to form a
polymeric matrix that is stabilized through a network of noncovalent interactions. The
CaM- based polymer will consist of alternating CaM and ‘collagen-like’ structural units.
We will refer to these polymers as CaM-collagenlike polymers, or CCLPs. Conversely,
the peptide-based polymers will consist of alternating M13 peptide and collagen-like
sequences, which will be termed peptide-collagenlike polymers, or PCLPs. What is
unique about these collagen-like sequences is that they have been chosen for their natural
ability to degrade because they are cleavage sites for matrix metalloproteinases, also
known as MMPs (and collagenases). The MMP-cleavable sequences have been
extensively noted for their application in creating biodegradable hydrogels [14-17].
While constructing these collagen-like sequences, we have incorporated three repeating
type I collagen-derived MMP cleavable sequences, GPQG/IWGQ, into the CaM and
M13-based protein polymers. These collagen-derived sequences are also interspaced by
the pentapeptide sequence GSGYG that serve the purpose of a functionalization site for
the attachment of drugs (-OH groups on the side chains of Serine (S) and Tyrosine (Y)).
Through exploitation of calcium concentration in the extracellular space, which
strengthens the interactions between M13 peptide and calmodulin, the spacer-peptide and
spacer-calmodulin alternating copolymers will assemble into a matrix in vivo in the EC
space [18]. Thus, upon assembling into the 3D matrix in the presences of Ca2+, the
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biomaterial will also be capable of biodegradation through the MMPs so that the matrix is
labile during inflammation, which is the intended use for the biomaterial.
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CHAPTER 3
EXPERIMENTAL APPROACH
This section describes the two iterations of the toxicity assay that were performed.
The first experiment, the Intermediate Toxicity Assay, observed the effect of CaM and
M13 materials over a maximum of 8 hours of cell growth. The second experiment, the
Long-term Toxicity Assay, observed the effect of CaM and M13 materials over a 24 hour
period. All details of the experiment are discussed below.
Intermediate Toxicity Study
The immediate toxicity study was the first of two tests conducted on the biomaterials
in order to determine the viability of cells when directly introduced to CaM and M13
materials. In this experiment, non-serum medium and a single cell line was to be used.
This provides the opportunity for the biomaterials to be the only thing that affects cell
viability. Therefore, the cells were washed in non-serum medium and directly exposed to
the biomaterials for four, six and eight hours as a foundational experiment to inform the
Long-term Toxicity Assay.
Long-Term Toxicity Study
While the purpose of the intermediate study was to gain an immediate understanding
of the effect of the biomaterials on the cells, the aim of the long-term study is slightly
different. The long-term study was conducted over 24 hours to determine the toxicity of
the biomaterials that were exposed to live cells contained in serum medium for a longer
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period of time. As such, this experiment differes from the Intermediate Toxicity Assay in
two ways: the time frame is 3x longer and there is protein in the medium along with our
test materials. This second assay provides a more accurate representation of how the
cells will respond to foreign biomaterials in vivo. Two different cell lines are also to be
used in this experiment.
INTRODUCTION TO CYTOTOXICITY TESTING
Since the proposed research materials will be released inside the human body, it is
essential that the protein-based polymers are assessed for cytotoxicity, and mammalian
cells are tested for viability upon exposure to the biomaterials. Given the fact that
cytotoxic experiments are more biological in nature, collaboration with other departments
with access to expertise, equipment, and appropriate materials was established. Dr.
Shabana Khan, a principal scientist in the Natural Products Research Center, served as
my direct mentor for these studies, granted me access to her lab, and provided me
guidance for all aspects of the toxicity assays. There are several different assays that are
based upon various cell functions such as enzyme activity, cell membrane permeability,
cell adherence, ATP production, co-enzyme production, and nucleotide uptake activity
[19]. The route in which I will gauge the cytotoxicity of the biomaterials is through the
means of cell viability and cytotoxicity assays, which are used for drug screening and
cytotoxicity tests of chemicals [19]. The assay that is used in this experiment is the MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction
assay.
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Theory of Cytotoxicity Testing
In order to determine the viability of the cells and toxicity levels of the protein
and peptide biomaterial a cell viability assay was performed. Cell viability and
cytotoxicity assays are used for drug screening and cytotoxicity tests of chemicals [19].
There are various reagents that are used for cell viability detection, and they are all based
upon various cell functions such as enzyme activity, cell membrane permeability, cell
adherence, ATP production, co-enzyme production, and nucleotide uptake activity [19].
The different various reagent used in cytotoxicity assays can be seen in in Figure 5.

Figure 5: Schematic of different cell viability assays and associated dyes. (Figure taken
from [19].)
Figure 5 demonstrates the different avenues that can be exploited when testing for
cytotoxicity. Some of these are more advanced techniques that are expensive and more
along the lines of antigenicity, while I am assessing solely toxicity. The best and most
cost-efficient assays for determining cell toxicity are enzyme-based methods, such as
MTT and WST-8. These methods are easy-to-use, safe, and have a high reproducibility
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[19]. The MTT technique, labeled as A in the MTT formazan dyes are based upon a
colorimetric method and are best known for determining mitochondrial dehydrogenase
activity within living cells [19]. The luciferase (bioluminescence) method, labeled as B,
is an ATP detection reagent that contains a detergent that is used to lyse the cells and
measure the amount of ATP that is released from the lysed cells [20]. While this assay is
the fastest and most sensitive assay to use, it was not ideal for our experiment, as we wish
to keep the cells alive and monitor them for as long as possible. Another possible choice
was the radioactively labeled thymidine approach. In the Tritium-labeled thymidine
uptake method, labeled as C, [3H]-thymidine is involved in the cell nucleus due to the
cell growth, and the amount of the tritium in the nucleus is then measured using a
scintillation counter. While this approach is sensitive to determine the influence on the
DNA polymerization activity, it requires use of a radioisotope which raises the problem
of laboratory and environmental safety [19].
Cell-based assays are often used for screening collections of compounds to determine
if the test molecules have effects on cell proliferation or to show direct cytotoxic effects
that eventually lead to cell death [20]. These methods allow for the researcher to estimate
the number of viable cells after exposure to the materials that are under study.
Regardless of the type of cell-based assay used, it is important to know how many viable
cells are remaining at the end of the experiment [20]. In order to determine the toxic
effect of the test materials, negative and positive controls must be run. In these
experiments negative control means that the cells survived, so conditions are such that the
cells should grow, and growth is monitored over the same timeframe as the growth of the
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cells in test materials. The positive control is the addition of ethanol, and agent that kills
the cells. Thus, “positive” means that the growth was suppressed; the cells died.
While there are a variety of assay methods that can be used to estimate the number of
viable eukaryotic cells, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) tetrazolium reduction assay technology has been widely adopted and remains
popular in academic labs as evidenced by thousands of published articles [20]. MTT falls
under the category of an enzyme-based method. These types of methods rely on
reductive coloring reagents, as well as the active dehydrogenase activity within viable
cells, in order to determine the cell viability via a colorimetric method [19]. The MTT
assay is well known and the most widely used method for determining the mitochondrial
dehydrogenase activity within living cells. In this assay, MTT is a positively charged
compound, and can therefore readily penetrate viable cells. The NADH that is produced
within the mitochondria of a living cell acts as an oxidizing agent to reduce the MTT,
thereby forming purple needle-shaped crystals within the cells (Figure 6) [19].

Figure 6: Reduction of MTT to Formazan. (Figure taken from [19].)
Figure 6 illustrates how the NADH within the mitochondria of a living organism
causes the reduction of nitrogen within the structure of MTT, producing the formazan
product. The exact cellular mechanism of MTT reduction into formazan is not well
understood; however, the reaction most likely involves interaction with a reducing
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molecule, such as NADH, that transfers electrons to MTT [21]. Despite broad
acceptance of this assay, neither the subcellular localization, nor the biochemical events
involved in MTT reduction are known [22]. The MTT dye is yellow, and once reduced
into formazan, it turns purple.
This formazan product of the MTT tetrazolium accumulates as a precipitate
within the cell, as well as being deposited near the cell surface and in the culture medium
[23-25]. Before absorbance readings can be taken, the formazan must be solubilized.
There are a variety of different methods used to stabilize the formazan product, but the
method that I used was solubilization with DMSO. The DMSO used in this experiment is
crucial, as it solubilizes the reagent and promotes its transfer through the cell membrane
so that it is uniformly distributed theough the overlaying liquid. Once the formazan has
been solubilized, the plate can then be read. While the MTT assay is an extremely easy
and efficient method in determining toxicity, it also has a few limiting factors as well.
One limitation is that the amount of signal that is generated when the plate is read is
dependent upon several parameters. These include: the concentration of MTT within
each well, the length of the incubation period, the number of viable cells within each
well, and the metabolic activity of the cells. The last parameter is especially important,
because when the cells die, they lose the ability to convert MTT into formazan [20].
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CHAPTER 4
MATERIALS AND METHODS
Media and Buffers
RMPI media (Roswell Memorial Park Institute) is a growth media for cells. It
contains a carbonate/HEPES pH buffer system with vitamins, glucose, and amino acids
added. The RPMI medium is used to culture the PK1 cell line. DMEM is the growth
media used for the HepG2 cells. Its full name is Dulbecco’s Modified Eagle’s Medium
and contains 4500 mg/L glucose and sodium bicarbonate, without L-glutamine and
sodium pyruvate, liquid, and is sterile-filtered.
Cell Lines
The choice of an appropriate cell line for this study proved to be a very important
task, as there are several different perpetual cell lines that cultured in Dr. Khan’s lab.
Through the guidance and direction of Dr. Khan, it was made clear to me that testing our
materials on human cell lines made the most sense, as the drugs are eventually intended
for use on mammals. The next step was to determine which types of cells would be most
viable for study. While cancerous cell lines were a viable option, Dr. Khan and I thought
that it would be most efficient to test the materials on normal, healthy mammalian tissue.
Therefore, the two cell lines that were chosen were pig kidney and human liver cell lines
(LLC-PK1 and HepG2). The cell lines were obtained from ATCC (Manassas, VA;
www.atcc.org). one of the cell lines chosen was a cancerous mammalian cell line, while
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the other was a normal, healthy mammalian cell line. Dr. Khan and her research team
sub-culture all of their cell lines on a weekly basis. From the cultures of cells that her
research team had, I was given my own two cell lines to sub-culture. Using aseptic
techniques, I followed a protocol to sub-culture the cells and seed the plates with the cell
lines for testing.
HEPG2
HepG2 is one of the perpetual cell lines used in this research. HepG2 is a human
liver carcinoma cell line derived from the liver tissue of a 15-year-old Caucasian male
(Figure 7).

Figure 7: HepG2 cells underneath a microscope shown growing to the correct
confluency.[26]
Since HepG2 cells are from liver epithelial cells, they secrete many plasma
proteins, such as transferring, fibrinogen, plasminogen and albumin. These cells are
adherent and epithelial-like in nature, as they grow in monolayers and in small
aggregates. HEPG2 cells are grown in a buffer medium called DMEM. This medium
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contains no proteins, lipids, or growth factors. This is perfect for my experiment because
the concentrations of the proteins and peptides that I am testing in this experiment are
very small. In order to minimize the interactions of the proteins and other particles in the
buffer medium, the DMEM was not supplemented with serum, such as 10% Fetal Bovine
Serum (FBS). This allows for only our protein and peptide to come into contact with the
cells and keeps the proteins in the medium from interfering with the materials that are
being tested. This non-serum medium doesn’t allow for the cells to grow, so the
experiment had to be carried out in a timely manner in order for the cells to be tested
while they were still alive. This is why the experiment only lasted for the duration of
eight hours, rather than a few days like some other MTT assays run.
LLC-PK1 cell line
The LLC-PK1 cell line was derived from the kidney of a normal, healthy male pig
that was between 3 and 4 weeks of age (Figure 8). [27]

Figure 8: LLC-PK1 epithelial cells under a microscope shown grown to confluence [27].
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The LLC-PK1 line, like the HEPG2 cell line, also exhibits typical epithelial
morphology and is often used as a model for epithelial tissue, as well as in a wide
spectrum of pharmacologic and metabolic research investigations. The buffer used to
grow the PK1 cell line is an RPMI buffer. The RPMI medium is unique from other
medium as it contains the reducing agent glutathione and high concentrations of vitamins,
such as inositol and choline, which are present in very high concentrations.
Cell Toxicity Protocol
Overview of Cell Preparation
A major parameter of this experiment is making sure that each cell within the 96 well
plate is seeded to the correct density of 5,000 cells per well. This means that the cells
must be taken from their liquid culture and counted to ensure that all wells contain the
same number of cells. If the cell count for each well is not the same, then the data could
be skewed. Therefore, the cells from each cell line are grown in a liquid culture to a
specific density. This density is then read with a cell counter and correctly aliquoted into
each well and grown to the proper confluency.
Day 1: Prepare the Cells
Cell Count
In order to make sure there are 5,000 cells in each well of the three 96 well plates, a
cell count was done on the cell suspension using the Bio-rad TC20TM automated cell
counter. The sample of cells were loaded onto a slide and inserted into the cell counter.
The TC20 cell counter then performed an auto-calibration process that calibrates the
machine to the specific cell line under study. The TC20 automated cell counter then
counted the mammalian cells in one simple step using its auto-focus technology and
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sophisticated cell counting algorithm. This process is repeated twice, and the average is
taken of the two readings to determine the average number of cells contained within the
cellular suspension. While this process is not completely accurate, it is the most
advanced process available to estimate the cell count for cultured cells.
Seeding the plates
The following formula was used to determine the appropriate volume needed to plate
the cells at 5,000 cells in each 96 well plate: (D1)*(V1) = (D2)*(V2). D1 is the density of
the cells, which is the cell count, D2 is the desired cell count, V2 is the final volume, and
V1 is the start volume. V1 was the unknown and the volume needed in order to determine
how much of the cell suspension to add to the DMEM media in order to have enough
volume to seed three 96 well plates. At this point, 100 µL of cells were added into each
well using a multi-channel pipet man. The plates were then placed in the incubator at
37oC and 5% CO2 for 24 hours in order to grow the cells to the proper confluence.
Day 2: Treatment of cells with biomaterials
The CaM protein started out at a stock concentration of 100µM and the M13 peptide
at a stock concentration of 50µM. The biomaterials for the intermediate toxicity study
were junction constructs of protein and peptide material. The biomaterials in this
experiment were CaM and M13, but they were not the constructs that are laid out in
Figure 1. In the subsequent long-term toxicity study, the CCLP construct mentioned in
Figure 1 was then tested. Prepping the materials requires a serial dilution in order to get
both the protein and peptide to the same working concentrations to be used during
testing. (Fig 9, 10)
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Figure 9: Serial dilution scheme for protein

Figure 10: Serial dilution scheme for peptide
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In this experiment, as mentioned above, two different controls were used. The
positive control was 100% ethanol, which should kill all of the cells. The negative
control was HEPES buffer, which is the buffer in the stock concentration of protein and
peptide. The wells of the plates in the intermediate and long-term toxicity studies were
exposed to our biomaterials and control components according to the schematic in Table
1. The plates were then left to incubate for their respective time periods
Intermediate

Protein

Peptide

Control

2μM

0.2μM

0.02μM

2μM

0.2μM

0.02μM

(+)2μM

(+)0.2μM

(+)0.02μM

2μM

0.2μM

0.02μM

2μM

0.2μM

0.02μM

(-)2μM

(-)0.2μM

(-)0.02μM

Long-Term
protein
HEPG2

(+)2µM

control
(+)0.2µM (+)0.02µM

1st rep

(+)2µM

(+)0.2µM

(+)0.02µM

2nd rep

(-)2µM

(-)0.2µM

(-)0.02µM

3rd rep

(-)2µM

(-)0.2µM

(-)0.02µM

(+)2µM

(+)0.2µM

(+)0.02µM

1st rep

(+)2µM

(+)0.2µM

(+)0.02µM

2nd rep

(-)2µM

(-)0.2µM

(-)0.02µM

3rd rep

(-)2µM

(-)0.2µM

(-)0.02µM

2µM

PK

0.2µM

peptide

0.02µM

2µM

0.2µM

0.02µM

Table 1: Testing concentration of the biomaterials in the intermediate and long-term
toxicity assay respectively
MTT assay protocol
All the media was carefully removed from each well of the 96 well plate via pipet
tip attached to a hose and suction nozzle. The MTT stocking solution was then prepared,
which is 5 mg of MTT in 1 mL of PBS. The MTT working solution was prepared, which
is a 1:10 dilution of MTT stocking solution into non-serum media. Next, 100 uL of MTT
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working solution was added into each well. Several wells were left as control with media
and no added MTT. The plates were then allowed to incubate for two hours to allow for
the MTT to be taken up and reduced by the cells. After the incubation period, the plate
was then shaken lightly on a rotating plate shaker for two minutes. Afterwards, all media
was removed and 200 uL DMSO was added to each well in order to dissolve the
formazan crystals. The plate was then read at 570 nm using a microplate reader.[28]
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CHAPTER 5
RESULTS
Data Processing
The cellular viability in each well was measured by UV-Vis spectroscopy with the
micro plate reader. The results from the experiment were values ranging from 0 to
around 0.3; Zero was the value for no growth (ethanol control) and 0.3 was the highest
value for the cells that grew. In order to determine the average amount of growth for the
respective concentrations, 2 µM, 0.2µM, and 0.02 µM, a few calculations were
performed. Firstly, the average growth contained in the negative control wells was taken.
The negative control is a buffer solution that allows for normal cellular growth; therefore,
it is the control to which all growth data were compared. Second, the average was taken
of the numbers for each respective biomaterial concentration. As an example, the
intermediate toxicity study only had an average of two wells, while the long-term study
had an average of four wells. Lastly, the average of each protein and peptide
concentration was divided by the average concentration of the negative control and
multiplied by 100. We first did an assessment of the trends in cell growth as a function
of time by simple comparison of the controls (Table 2). The relative growth values for
the Calmodulin and M13-peptide samples are plotted in the bar graphs in Figure 11, and
12. The error bars are the standard deviation in the average.
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To assess whether cell were killed by ethanol (positive control), we compared the
background absorbance of the a empty well to the ethanol added cells. They were
identical to the third decimal places (~0.100 AU) with the exception of the 6 hour time
point (Table 2; discussed below). Next we compared this value to that for negative
control (added buffer) for the 4, 6 and 8 hour time points. At each time point the growth
in the negative samples exceeded the positive control, as we would have predicted. This
difference means that cells in the Live Well samples were growing. The difference
between the Live Well and Positive control values led to an estimate of the growth of
cells as a function of incubation time. Notice that the signal from MTT approximately
doubled every two hours of incubation (starting at the 4 hour time point).

Hours
4
6
8

Comparison of the Controls
Live Well(-)
Dead/Empty(+)
0.100±0.012
0.125±0.002
0.132±0.008
0.198±0
0.109±0.007
0.187±0.077

Difference
0.025±0.012
0.066±0.008
1.013±0.077

Table 2: Calculations of the average growth with standard deviations of the positive and
negative control wells.
Regarding the 6-hour time point, the absorbance reading for both the positive control
and the Live Well samples exceeds the other time points, but the difference between them
shows growth in an intermediate range. This fact indicates that these data are elevated by
some extraneous factor, like a plate that was scarred or otherwise had a partially
obstructed optical surface.
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Figure 11: Results from the intermediate toxicity study with standard deviation bars (I)
included to show the differences in growth between the samples.
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Intermediate Toxicity Assay
Results from the intermediate toxicity study can be seen in Figure 11. This figure
shows the results from the three different plates that were under study. The preliminary
test data from the intermediate cytotoxicity assay shows that the protein (CaM) and
peptide (M13) from the four hour study, at 2 µM, 0.2µM, and 0.02 µM concentrations,
are not toxic to the HEPG2 cells. Based upon the data from the assay, the protein and
peptide actually promote cellular growth in the cell cultures at the 4 hour time point,
which is a normal response to cells being treated with a protein source. In the six hour
study, the results are inconsistent. Eventhough there is more overall growth, there is no
systematic trend as a function of the concentration of added protein or peptide. At 8
hours, growth in the presence of added protein or peptide is indistinguishable from the
negative control (growth in buffer only). In conclusion there was a short term effect of
added Calmodulin protein or M13-peptide, but no longterm effect.
Long-term cytotoxicity study
The second part of the objective 3 in this research plan was to perform a study that
would demonstrate the viability of cells over a longer period of time. While the
intermediate toxicity test allowed for controlled and quick assessment of cell viability,
incubation of cells with the biomaterials for a longer period of time will simulate the
exposure of the protein and peptide in vivo within the human body. Also, since there was
no seum in the intermediate toxicity study, growth may be limited by the availability of
protein as a food source. Another distinct difference in the long-term study from the
intermediate study was the testing of the CCLP construct. The CaM used in the
intermediate study was isolated calmodulin, not the construct shown in Figure 1.
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However, the CaM used in the long-term study was in fact the construct that is seen in
Figure 1, the actual construct that will be used to created the biomaterials at a later time.
Additionally, another distinct difference is that two different cell lines were used in this
experiment. The cell line LLC-PK1 was studied in conjunction with HEPG2. The results
from the 24-hour study can be found below in Figure 12.
The results from this experiment correlate directly with the results from the
intermediate toxicity experiments and show that the protein and peptide actually enhance
the growth of the cells. Both the protein and peptide seem to act in a food-like manner
for the cells to feed off of instead of actually inhibiting growth at the cellular level.
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Figure 12: Results from the 24-hour plate with standard deviation bars (I) showing
enhanced growth of both cell lines. (Top: both cell lines, Middle and bottom: Individual
cell lines)

37

DISCUSSION
Trends in Intermediate Toxicity Study
Controls: The results showed that at four and eight hours the positive control
wells had almost identical readings and were normalized against the testing
concentrations with low error. However, at the six-hour mark, there was a larger amount
of growth in the positive control wells for no apparent reason. The positive control
should kill all cellular growth at a constant and measurable difference. Furthermore,
from analyzing the difference between the dead and live wells, it is evident that there is a
doubling in growth every two hours between the positive and negative control wells.
This indicates that there is essentially a linear progression between the two controls.
There were no biomaterials in these wells, which indicates that the control wells were not
running out of materials on which they could grow.
Test of peptide and protein: Since cells were not limited on materials for growth, it
can be deduced that the wells that with added biomaterials were also not running out of
fuel on which they could grow, because even the control wells that contained no cellular
growth medium were still growing at all time periods. With that being said, it is evident
that the biomaterials that are added to the testing wells are essentially used up fairly
quickly within the four to six hour marks. Then, the cells return to a normal and stable
growth phase where the growth is almost equal to the amount of cellular growth with no
added biomaterials.

38

Long-term toxicity experiments showed much more overall growth of cells, and the
test wells far exceeded the negative controls. This observation is consistent with the
interpretation that added serum/protein/peptide promotes growth of cells overall. The
limitation of these experiments is that it is impossible to parse whether there is a
contribution from the added protein/peptide or not. In future studies, we should add an
additional control well with serum added, but no test materials.
Failure to Express PCLP
The PCLP construct that is laid out in Figure 1 was never correctly expressed. While
the CCLP construct was correctly expressed and purified, several different attempts to
purify the PCLP construct designed by the Pedigo lab never came to fruition. While we
do not fully understand what is causing the problem, we speculate that two things might
be inhibiting the success of this experiment. Firstly, the protein was not expressed at
levels that this expression usually affords. We are not sure what the problem is, and in
fact, the problems varied with each successive attempt. Poor expression may be due to
secondary or tertiary folding of the construct as it rolls off the ribosome that leads to
premature termination of translation. Secondly, there are multiple hydrophobic residues
contained within the PCLP construct that might cause the peptide to fold inwards upon
itself, burying the His6 affinity label. Because of this, the PCLP would not purify
correctly during the His-Tag purification process.
Dilution of Protein Concentrations
The concentration of biomaterials that are being tested in these two assays is very
low. The working concentrations of 2 µM, 0.2µM, and 0.02 µM that were tested in these
experiments were relatively small, compared to other studies that have been performed
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by Jing and others in the past [29]. Being that the concentration of our biomaterials is so
small, the nature of the media in which we use for the trials was very important. For the
intermediate toxicity assay, I worked with Dr. Khan to devise an experiment that would
allow for maximum interaction of our biomaterials with the HEPG2 cells. The problem
that I aimed to address was minimizing interactions of our protein and peptide with the
serum proteins and various additives that are often added to growth media. I wanted our
biomaterials to be the only thing in contact with the cells during the assay. The solution
that we came up with was the short-term exposure assay, which I have entitled
intermediate toxicity assay. This assay used a media that was not substituted with any
serum and contained no other proteins or peptides that could interfere with our
biomaterials to dilute their affects upon the cells. While this allowed for our biomaterials
to take the center stage in the assay, we believe it inhibited the growth of cells in the
assay. While there was overall growth over the 8 hour time frame, it was attenuated in
comparison to the 24 hour study. While most MTT assays are run over the course of 24
hours to several days, this intermediate toxicity assay was limited by the fact that the cells
were not contained in any serum-substituted media that would allow for them to grow.
The Importance of MTT and Cell Count
It is important to discuss the role of the MTT reagent in the cytotoxicity assay. MTT
is the sole reagent used in the assay. The addition of MTT to the wells puts the cells into
stasis and allows for them to be assessed for viability. When the MTT is added to each of
the wells, it uses the NADH that is produced by the mitochondria and the MTT is
converted into the formazan product. The amount of MTT that is converted into
formazan is what is measured by the microtitre plate reader; however, a parameter that
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affects this greatly is the amount of cells that are contained within each well. The rate of
conversion of MTT to formazan is directly dependent upon the amount of NADH that is
being produced by each cell within each well. Therefore, making sure that each well has
the exact same number of viable cells is crucial because the metabolic activity of each
cell is being directly measured through the use of the MTT reagent. While there is not a
definite way to make sure that each well contains the exact same amount of cells, extreme
care was taken to make sure that the cells were counted and aliquotted correctly. The use
of repeats, as seen in the long-term study, also minimized the chances for error and
helped standardize the mean number of cells per well.
In conclusion, this work was successful in many respects. It establishes a working
relationship with Dr.S. Khan allowing the Pedigo lab, thereby broadening the tools
available for assessment of the biomaterials under development there. Secondly, these
experiments will inform any future efforts along these lines. The cell lines were and
MTT technology seemed to work as planned. We changed the growth media between the
two experiments. The take-home message there is that we should increase the
cconcentration of the test materials and make sure that serum is present in the growth
media for both the peptide/protein added test samples and a “negative”control.

41

REFERENCES
1.

Nelson, M.R. and W.J. Chazin, Calmodulin as a calcium sensor, in Calmodulin
and Signal Transduction, L.J. Van Eldik and D.M. Watterson, Editors. 1998,
Academic Press: San Diego. p. 17-64.

2.

Sorensen, B.R. and M.A. Shea, Interactions between domains of apo calmodulin
alter calcium binding and stability. Biochemistry, 1998. 37(12): p. 4244-53.

3.

Evans, T.I.A., J.W. Hell, and M.A. Shea, Thermodynamic linkage between
calmodulin domains binding calcium and contiguous sites in the C-terminal tail
of CaV1.2. Biophys Chem, 2011. 159: p. 172-187.

4.

Babu, Y.S., C.E. Bugg, and W.J. Cook, Structure of calmodulin refined at 2.2 A
resolution. J Mol Biol, 1988. 204(1): p. 191-204.

5.

Malencik, D.A. and S.R. Anderson, High affinity binding of the mastoparans by
calmodulin. Biochem Biophys Res Commun, 1983. 114(1): p. 50-6.

6.

Cox, J.L. and S.D. Harrison, Jr., Correlation of metal toxicity with in vitro
calmodulin inhibition. Biochem Biophys Res Commun, 1983. 115(1): p. 10611.

7.

Blumenthal, D.K., et al., Identification of the calmodulin-binding domain of
skeletal muscle myosin light chain kinase. Proc Natl Acad Sci U S A, 1985.
82(10): p. 3187-91.

42

8.

Rhoads, A.R. and F. Friedberg, Sequence motifs for calmodulin recognition.
FASEB J, 1997. 11(5): p. 331-40.

9.

Crivici, A. and M. Ikura, Molecular and structural basis of target recognition by
calmodulin. Annu Rev Biophys Biomol Struct, 1995. 24: p. 85-116.

10.

Cox, J.A., et al., The interaction of calmodulin with amphiphilic peptides. J Biol
Chem, 1985. 260(4): p. 2527-34.

11.

Li, H., A.D. Robertson, and J.H. Jensen, The determinants of carboxyl pKa values
in turkey ovomucoid third domain. Proteins: Structure, Function, and
Bioinformatics, 2004. 55(3): p. 689-704.

12.

Browne, J.P., et al., The role of beta-sheet interactions in domain stability,
folding, and target recognition reactions of calmodulin. Biochemistry, 1997.
36(31): p. 9550-61.

13.

Clore, G.M., et al., Structure of calmodulin-target peptide complexes. Current
Opinion in Structural Biology, 1993. 3: p. 838-845.

14.

Bracher, M., et al., Cell specific ingrowth hydrogels. Biomaterials, 2013.
34(28): p. 6797-803.

15.

Lee, S.H., et al., Proteolytically degradable hydrogels with a fluorogenic
substrate for studies of cellular proteolytic activity and migration. Biotechnol
Prog, 2005. 21(6): p. 1736-41.

16.

Lutolf, M.P. and J.A. Hubbell, Synthesis and physicochemical characterization
of end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michaeltype addition. Biomacromolecules, 2003. 4(3): p. 713-22.

43

17.

Lutolf, M.P., et al., Synthetic matrix metalloproteinase-sensitive hydrogels for
the conduction of tissue regeneration: engineering cell-invasion characteristics.
Proc Natl Acad Sci U S A, 2003. 100(9): p. 5413-8.

18.

Andreev, O.A., et al., Mechanism and uses of a membrane peptide that targets
tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A, 2007.
104(19): p. 7893-8.

19.

Dojindo. Measuring Cell Viability and Toxicity.

20.

Riss, T., et al., Cell Viability Assays, in Assay Guidance Manual [Internet], G.
Sittampalam, N. Coussens, and K. Brimacombe, Editors. 2013 [Updated
2016], Eli Lilly & Company and the National Center for Advancing
Translational Sciences: Bethesda, MD. p. 1-31.

21.

Marshall, N.J., C.J. Goodwin, and S.J. Holt, A critical assessment of the use of
microculture tetrazolium assays to measure cell growth and function. Growth
Regul, 1995. 5(2): p. 69-84.

22.

Berridge, M.V. and A.S. Tan, Characterization of the cellular reduction of 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular
localization, substrate dependence, and involvement of mitochondrial electron
transport in MTT reduction. Arch Biochem Biophys, 1993. 303(2): p. 474-82.

23.

Tada, H., et al., An improved colorimetric assay for interleukin 2. J Immunol
Methods, 1986. 93(2): p. 157-65.

24.

Hansen, M.B., S.E. Nielsen, and K. Berg, Re-examination and further
development of a precise and rapid dye method for measuring cell growth/cell
kill. J Immunol Methods, 1989. 119(2): p. 203-10.

44

25.

Denizot, F. and R. Lang, Rapid colorimetric assay for cell growth and survival.
Modifications to the tetrazolium dye procedure giving improved sensitivity and
reliability. J Immunol Methods, 1986. 89(2): p. 271-7.

26.

Muhammad Nadzri, N., et al., Inclusion Complex of Zerumbone with
Hydroxypropyl- beta -Cyclodextrin Induces Apoptosis in Liver Hepatocellular
HepG2 Cells via Caspase 8/BID Cleavage Switch and Modulating Bcl2/Bax
Ratio. Evid Based Complement Alternat Med, 2013. 2013: p. 810632.

27.

Negrette-Guzman, M., et al., Sulforaphane attenuates gentamicin-induced
nephrotoxicity: role of mitochondrial protection. Evid Based Complement
Alternat Med, 2013. 2013: p. 135314.

28.

Mosmann, T., Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Methods, 1983.
65(1-2): p. 55-63.

29.

Jing, et al, Self-Assembling Peptide-Polymer Hydrogels Designed From the
Coiled Coil Region of Fibrin. Biomaterials, 2008. 9: p. 2438-2446.

45

